RxDoctor Payments Data

David Garrison, MD

Internal Medicine · Milford, PANPI 1588635999

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 52 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$227
  • Amgen$153
  • AstraZeneca$133
  • Abbott$122
  • Lilly USA, LLC$119
  • Astellas Pharma US Inc$101
  • plus $266 from 6 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,122 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$122,970
Medicare patients
440
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$199,571
EliquisApixaban161$185,326
MounjaroTirzepatide72$103,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$74,268
FarxigaDapagliflozin Propanediol62$70,017
JardianceEmpagliflozin47$53,940
Tresiba Flextouch U-200Insulin Degludec31$48,921
Nurtec OdtRimegepant Sulfate16$45,976
OxycontinOxycodone Hcl27$34,088
XareltoRivaroxaban27$33,597
TrulicityDulaglutide16$29,710
Combivent RespimatIpratropium/Albuterol Sulfate28$25,005
ProliaDenosumab15$24,663
RybelsusSemaglutide25$23,257
ZenpepLipase/Protease/Amylase19$22,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$227$222,828156 claims
Lilly USA, LLCMounjaro, Trulicity$119$133,27688 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$133$99,588103 claims
Boehringer IngelheimJardiance, Combivent Respimat$11$78,94575 claims
AmgenProlia$153$24,66315 claims
Astellas Pharma US IncMyrbetriq$101$20,54235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Milford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →